Table 2.
Clinical pathological features of sox signature genes in three cohorts
| TCGA LIHC Cohort I (n = 188) | TCGA LIHC Cohort II (n = 189) | LIRI-JP Cohort (n = 231) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Low sox group | High sox group | P value | Low sox group | High sox group | P value | Low sox group | High sox group | P value | |
| Gender | 0.020 | 0.014 | 0.671 | ||||||
| Male | 104 (55.3%) | 28 (14.9%) | 100 (52.9%) | 23 (12.2%) | 141 (61.0%) | 30 (13.0%) | |||
| Female | 35 (18.6%) | 21 (11.2%) | 43 (22.8%) | 23 (12.2%) | 48 (20.8%) | 12 (5.2%) | |||
| Tumor Stage | 0.001 | 0.009 | 0.055 | ||||||
| I | 70 (37.2%) | 11 (5.9%) | 80 (42.3%) | 14 (7.4%) | 31 (13.4%) | 4 (1.7%) | |||
| II | 33 (17.6%) | 18 (9.6%) | 28 (14.8%) | 8 (4.2%) | 91 (39.4%) | 15 (6.5%) | |||
| III | 24 (12.8%) | 19 (10.1%) | 26 (13.8%) | 18 (9.5%) | 55 (23.8%) | 16 (6.9%) | |||
| IV | 1 (0.5%) | 0 (0%) | 2 (1.1%) | 1 (0.5%) | 12 (5.2%) | 7 (3.1%) | |||
| Tumor Grade | 0.026 | 0.126 | NA | ||||||
| G1 | 32 (17.0%) | 2 (1.1%) | 18 (9.5%) | 3 (16.7%) | NA | NA | |||
| G2 | 62 (33.0%) | 27 (14.4%) | 73 (38.6%) | 18 (9.5%) | NA | NA | |||
| G3 | 37 (19.7%) | 19 (10.1%) | 45 (23.8%) | 23 (12.2%) | NA | NA | |||
| G4 | 6 (3.2%) | 1 (0.5%) | 5 (2.6%) | 1 (0.5%) | NA | NA | |||
| Vascular Invasion | 0.003 | 0.001 | NA | ||||||
| Macro | 3 (1.6%) | 2 (1.1%) | 4 (2.1%) | 8 (4.2%) | NA | NA | |||
| Micro | 41 (21.8%) | 19 (10.1%) | 27 (14.3%) | 7 (3.7%) | NA | NA | |||
| None | 79 (42.0%) | 14 (7.4%) | 96 (50.8%) | 21 (11.1%) | NA | NA | |||